MENU
+Compare
IDNA
ETF ticker: NYSE ARCA
AS OF
Jan 17 closing price
Price
$21.91
Change
+$0.01 (+0.05%)
Net Assets
120.5M

IDNA stock forecast, quote, news & analysis

Category: @Health
IDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for IDNA with price predictions
Jan 08, 2025

IDNA sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for IDNA moved below the 200-day moving average on January 02, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IDNA broke above its upper Bollinger Band on January 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IDNA entered a downward trend on December 31, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IDNA's RSI Oscillator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 03, 2025. You may want to consider a long position or call options on IDNA as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IDNA just turned positive on January 03, 2025. Looking at past instances where IDNA's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IDNA advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX).

Industry description

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.

Market Cap

The average market capitalization across the iShares Genomics Immnlgy & Hlthcr ETF ETF is 19.61B. The market cap for tickers in the group ranges from 100.71M to 331.75B. MRK holds the highest valuation in this group at 331.75B. The lowest valued company is EDIT at 100.71M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Genomics Immnlgy & Hlthcr ETF ETF was -3%. For the same ETF, the average monthly price growth was -2%, and the average quarterly price growth was -10%. BPMC experienced the highest price growth at 26%, while SWTX experienced the biggest fall at -19%.

Volume

The average weekly volume growth across all stocks in the iShares Genomics Immnlgy & Hlthcr ETF ETF was -28%. For the same stocks of the ETF, the average monthly volume growth was -7% and the average quarterly volume growth was 54%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 72
Price Growth Rating: 63
SMR Rating: 84
Profit Risk Rating: 84
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
IDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com